BNTC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Benitec Biopharma Inc (BNTC) does not present a compelling buy opportunity at this time for a beginner investor with a long-term strategy. The technical indicators are mixed, with bearish moving averages and neutral RSI, while the options data suggests low trading activity. Additionally, the company's financial performance shows no revenue growth and continued losses, despite some improvement in net income. Without strong positive catalysts or significant institutional or insider buying, it is better to hold off on investing in this stock for now.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 54.741, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 11.51), suggesting limited upside potential in the short term.
Hedge funds have significantly increased their buying activity, with a 599.83% increase in the last quarter. This could indicate some institutional confidence in the stock.
No recent news or significant insider trading activity. The financials show no revenue growth and continued losses, with a net income of -$11.84M in the latest quarter. Additionally, there is no recent congress trading data or analyst rating updates to provide further confidence.
In Q2 2026, the company reported no revenue growth (0% YoY) and a net income of -$11.84M, which is an improvement of 23.92% YoY. EPS remained negative at -0.26, with no significant changes in gross margin. Overall, the financials are weak and do not suggest strong growth potential.
No recent analyst ratings or price target updates are available for BNTC.
